Stable lipid-comprising drug delivery complexes and methods for their production
Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.
1. A method for producing a noncovalent nucleic acid/lipid/polycation complex having a net positive charge at pH 6.0-8.0, the method comprising,
providing a cationic lipid and a polycation to form a lipid/ polycation complex, and
providing a nucleic acid with the lipid/polycation complex in a ratio of nucleic acid to lipid to polycation which results in the production of the nucleic acid/lipid/polycation complex,
wherein the polycation is a polycationic peptide or a polycationic protein.
2. The method of claim 1 , wherein the cationic lipid is a cationic liposome.
3. The method of claim 2 , wherein the cationic liposome further comprises a neutral lipid.
4. The method of claim 1 , wherein the polycation has a molecular weight of 300 to 200,000 Daltons.
5. The method of claim 1 , wherein the polycation is a polycationic peptide.
6. The method of claim 4 , wherein the polycationic peptide is a synthetic polycationic peptide.
7. The method of claim 5 , wherein the polycationic peptide is a synthetic peptide derived from SV40 large T antigen and has net positive charge and a nuclear localization sequence.
8. The method of claim 5 , wherein the polycationic peptide comprises lysine residues.
9. The method of claim 5 , wherein the polycationic peptide comprises polylysine.
10. The method of claim 1 , wherein the polycation is a polycationic protein.
11. The method of claim 10 , wherein the polycationic protein is a histone.
12. The method of claim 1 , wherein the polycation is a peptide comprising a nuclear localization sequence of SV40 large T antigen.
13. The method of claim 1 , wherein the polycation comprises spermine or spermidine.
14. The method of claim 5 , wherein the polycationic peptide comprises a natural polycationic peptide.
15. The method of claim 10 , wherein the polycationic protein is a protamine.
16. The method of claim 1 , wherein the ratio of lipid to nucleic acid ranges from about 0.1 nmol to 200 nmol lipid per 1 μg nucleic acid.
17. The method of claim 1 , wherein the ratio of lipid to nucleic acid ranges from about 1 nmol to about 25 nmol lipid per 1 μg nucleic acid.
18. The method of claim 1 , wherein the polycation:nucleic acid ratio is about 0.01 μg to about 100 μg polycation to 1 μg nucleic acid.
19. The method of claim 1 , wherein the lipid/polycation complex is stored for up to 120 days prior to providing the nucleic acid with the lipid/polycation complex.
20. The method of claim 1 , wherein the lipid/polycation complex is stored for up to a year prior to providing the nucleic acid with the lipid/polycation complex.
21. The method of claim 1 , wherein the lipid/polycation complex is stored for between four weeks and a year prior to providing the nucleic acid with the lipid/polycation complex.
22. The method of claim 1 , wherein the polycation is up to about 500 amino acids in length.
23. The method of claim 4 , wherein the polycation is a peptide comprising polylysine.